Cabozantinib Development Program

Discovered by Exelixis, and the focus of our development and commercialization efforts, Cabozantinib inhibits the activity of tyrosine kinases including MET, AXL, VEGF receptors, and RET and is recognized for its potential to treat a wide variety of cancers.
Download the PDF.

Filter by Therapeutic Area

Exelixis-Sponsored Trial

Roche-Sponsored Trial

Bristol Myers Squibb-Sponsored Trial

Investigator-Sponsored Trial

Collaboration with NCI’s Cancer Therapy Evaluation Program

Sponsored by the European Organisation for Research and Treatment of Cancer (EORTC)

Phase 1
Phase 2
Phase 3
Genitourinary (GU) Cancers
Cabozantinib + Nivolumab +/- CBM588
(Metastatic RCC)
Renal Cell Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CABIOS: Cabozantinib + Abiraterone + Nivolumab
(Metastatic Hormone-Sensitive Prostate Cancer)
Prostate Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Enfortumab Vedotin
(Locally Advanced or Metastatic UC)
Urothelial Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC-021: Cabozantinib
(Advanced UC)
Urothelial Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC-021: Cabozantinib + Atezolizumab
(Advanced RCC, Advanced UC & CRPC)
Renal Cell Carcinoma Urothelial Carcinoma Prostate Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Nivolumab ± Ipilimumab
Any GU Tumors

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Avelumab
(Metastatic Renal Cell Carcinoma)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Refractory Germ Cell Tumors)
Germ Cell Tumors

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Metastatic CRPC with Genomic Alterations)
Prostate Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Nivolumab + Ipilimumab
(Advanced Non-Clear Cell Renal Carcinoma)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cyto-KIK: CYTO Reductive Surgery followed by Cabozantinib + Nivolumab
(Metastatic RCC)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

ABATE: Cabozantinib + Atezolizumab
(Muscle-Invasive Bladder Cancer)
Bladder Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

PemCab: Cabozantinib + Pembrolizumab
(Metastatic UC Ineligible for Cisplatin)
Bladder Cancer Urothelial Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

RadiCaL: Cabozantinib + Radium–223 Dichloride
(Advanced RCC with Bone Metastasis)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Advanced or Metastatic Urothelial Carcinoma)
Urothelial Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Clear Cell or Non-Clear Cell Metastatic RCC)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

ATLANTIS: Cabozantinib
(Metastatic Urothelial Carcinoma)
Urothelial Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CONTACT-03: Cabozantinib + Atezolizumab vs. Cabozantinib
(Advanced RCC)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CONTACT-02: Cabozantinib + Atezolizumab vs. Second Novel Hormone Therapy
(Metastatic, Castrate-Resistant PC)
Prostate Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC-313: Cabozantinib + Nivolumab + Ipilimumab
(First-line Advanced or Metastatic RCC)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

PDIGREE: Nivolumab + Ipilimumab followed by Cabozantinib + Nivolumab vs. Nivolumab
(First-line Metastatic RCC)
Renal Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Gastrointestinal (GI) Cancers
Cabozantinib + TAS-102
(Metastatic Colorectal Adenocarcinoma)
Colorectal Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CAMILLA: Cabozantinib + Durvalumab
(Advanced CRC & HCC)
Colorectal Cancer Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib ± Nivolumab
(Neoadjuvant, Locally Advanced HCC)
Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC-021: Cabozantinib + Atezolizumab
(HCC & CRC)
Colorectal Cancer Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Pembrolizumab
(Metastatic Pancreatic Adenocarcinoma)
Pancreatic Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Atezolizumab
(Metastatic, Refractory Pancreatic Cancer)
Pancreatic Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Nivolumab
(Refractory Metastatic Microsatellite Stable CRC)
Colorectal Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Nivolumab/Ipilimumab and TACE
(Hepatocellular Carcinoma)
Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Advanced Hepatocellular Carcinoma with Child-Pugh Class B Cirrhosis after First-Line Therapy)
Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CheckMate 040 Subgroup: Cabozantinib + Nivolumab ± Ipilimumab
(First-line and Previously Treated Advanced HCC)
Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Refractory, Metastatic CRC)
Colorectal Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Pembrolizumab
(Metastatic or Recurrent Gastric or Gastro-Esophageal Adenocarcinoma)
Gastric or Gastro-Esophageal Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC-312: Cabozantinib + Atezolizumab vs. Sorafenib vs. Cabozantinib
(First-line Advanced HCC)
Hepatocellular Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Thyroid Cancer
COSMIC-021: Cabozantinib + Atezolizumab
(DTC)
Differentiated Thyroid Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(First-line, RAI-refractory DTC)
Differentiated Thyroid Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Lung Cancer
COSMIC-021: Cabozantinib
(NSCLC)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC-021: Cabozantinib + Atezolizumab
(NSCLC)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib vs. Cabozantinib + Nivolumab vs. Chemotherapy
(Previously Treated Non-Squamous NSCLC)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Molecular Alterations in RET, ROS1, MET, AXL, or NTRK1)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Nivolumab vs. Cabozantinib + Nivolumab vs. Cabozantinib + Nivolumab + Ipilimumab
(NSCLC)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CONTACT-01: Cabozantinib + Atezolizumab vs. Docetaxel
(Metastatic NSCLC)
Non-Small Cell Lung Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Gynecologic Cancers
COSMIC-021: Cabozantinib + Atezolizumab
(EC, Ovarian Cancer & Breast Cancer)
Breast Cancer Ovarian Cancer Endometrial Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Nivolumab ± Cabozantinib
(Advanced or Metastatic EC)
Endometrial Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Neuroendocrine Tumors (NET) & Carcinoid
Cabozantinib
(Neuroendocrine Neoplasms)
NET & Carcinoid

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Nivolumab + Ipilimumab
(Poorly Differentiated Neuroendocrine Carcinomas)
NET & Carcinoid

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Nivolumab
(Advanced Carcinoid Tumors)
NET & Carcinoid

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Advanced Pancreatic NET & Advanced Carcinoid)
NET & Carcinoid

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CABINET: Cabozantinib vs. Placebo
(Advanced Neuroendocrine Tumors After Progression on Everolimus)
NET & Carcinoid

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Adrenocortical Carcinoma
Cabozantinib
(Metastatic Pheochromocytomas and Paragangliomas)
Adrenal Tumors

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Metastatic Adrenocortical Carcinoma)
Adrenal Tumors

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Sarcoma
Cabozantinib + Nivolumab (Taxane Pre-treated) vs. Pacitaxel ± Nivolumab (Taxane Naïve)
(Angiosarcoma)
Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + PD-1 and CTLA-4 Inhibition
(Metastatic Soft Tissue Sarcoma)
Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Radiation Therapy
(Sarcomas of the Extremities)
Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Temozolomide
(Unresectable or Metastatic Leiomyosarcoma and other Soft Tissue Sarcomas)
Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib vs. Placebo
(High-Grade Uterine Sarcoma)
Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Metastatic Soft Tissue Sarcoma)
Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Neurofibroma
Cabozantinib in Plexiform Neurofibromas
Neurofibroma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Gastroesophageal Cancer
CAMILLA: Cabozantinib + Durvalumab
(Advanced Gastric, Gastroesophageal or Esophageal Adenocarcinoma)
Gastroesophageal Cancer Esophageal Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC-021: Cabozantinib + Atezolizumab
(Gastric or Gastroesophageal Junction Adenocarcinoma)
Gastroesophageal Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Head and Neck Cancer
Cabozantinib + Cetuximab
(Recurrent, Metastatic Squamous Cell Carcinoma)
Squamous Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

COSMIC-021: Cabozantinib + Atezolizumab
(Head and Neck Cancer)
Head and Neck Cancer

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Pembrolizumab
(Recurrent, Metastatic Squamous Cell Carcinoma)
Squamous Cell Carcinoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Melanoma
Cabozantinib + Pembrolizumab
(Advanced, Metastatic Melanoma)
Melanoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib + Nivolumab + Ipilimumab
(Unresectable, Advanced Melanoma)
Melanoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Pediatric Cancer
Cabozantinib + Retinoic Acid
Pediatric Multiple Tumor Types

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CaboMain: Cabozantinib
(High-risk Pediatric Solid Tumors)
Pediatric Multiple Tumor Types

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib in Plexiform Neurofibromas
Pediatric Neurofibroma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

CABONE: Cabozantinib
(Osteosarcomas and Ewing Sarcomas; Patients 12+)
Pediatric Sarcoma

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Cabozantinib
(Refractory Sarcoma, Wilms Tumor, Other Rare Tumors)
Pediatric Multiple Tumor Types

You are now leaving the Exelixis.com site and moving to an external website independently operated and not managed by Exelixis, Inc. Exelixis assumes no responsibility for the site.

If you do not wish to leave this site, click Cancel. Or, click Continue

Other Partnered Compounds

We are also advancing cancer treatment through collaborations.